TABLE 1.
Phospholipid composition of the strains used in this study
| Lipid phenotype | Strain (amt of aTc used [ng/ml])a | Amt (mol%) of indicated phospholipidb |
Other phospholipid(s) (amt [mol%]) | Reference(s) | |||
|---|---|---|---|---|---|---|---|
| PE | PG | CL | PA | ||||
| WT | AL95/pDD72GM | 78 | 12 | 6 | <3 | 12 | |
| Modulated PE | AT2033 (500) | 75 | 14 | 8 | <3 | 31 | |
| AT2033 (100) | 30 | 25 | 35 | <2 | 31 | ||
| AT2033 (20) | 17 | 40 | 40 | <2 | 31 | ||
| AT2033 (0) | 2 | 45 | 50 | <2 | 31 | ||
| Minus PE | AL95 | 0 | 45 | 50 | 3 | CDP-DAG | 22 |
| Minus CL | BKT12 | 79 | 18 | 0 | <2 | 15 | |
| Minus PG/CL | UE54 | 92 | 0 | 0 | 4 | CDP-DAG (3), N-acyl PE (0.4) | 23, 44 |
a
PE levels in strain AT2033 were modulated by using anhydrotetracycline (aTc) in the indicated concentrations.
b
Composition data for strains grown to mid-exponential phase in LB medium are shown. PE, phosphatidylethanolamine; PG, phosphatidylglycerol; CL, cardiolipin; PA, phosphatidic acid; CDP-DAG, cytidine diphosphate diacylglycerol.